This week on Tech Can't Save Us, host Paul David is joined by Julio Martinez-Clark, co-founder and CEO of BioAccess, the world's first contract research organization (CRO) purpose-built specifically for first-in-human (FIH) clinical trials. They discuss the "valley of death" that claims roughly 90% of healthcare startups, which frequently fail not because their technology is flawed, but because they run out of capital before securing vital clinical data.
Julio explains how BioAccess helps medtech, biopharma, and radiopharma startups bypass these bottlenecks by compressing clinical timelines by 40% through efficient, predictable site selection and activation in regulatory-friendly Latin American markets. The conversation covers BioAccess's self-funded growth strategy, common pitfalls made by first-time founders, and how providing low-income patients with compassionate, advanced healthcare brings dignity back to clinical research. Julio also reflects on his time writing his book, La Cebolla de Pandora, and how that period of reflection shaped his deep commitment to prioritizing human impact over profit.
Healthcare startups face a high monthly burn rate averaging $300,000 to $400,000, making rapid first-in-human clinical data crucial to surviving the "valley of death" before they can raise more capital or secure an exit. Cost-efficiency in Latin American clinical settings does not mean lower standards, as all trials strictly adhere to the international ICH and GCP guidelines required by the FDA and EMA.
By leveraging an extensive network of hospitals and regulatory-friendly environments in countries like Panama and El Salvador, BioAccess achieves rapid site activation and patient recruitment.
Beyond the B2B framework, accelerating these trials democratizes access to life-saving medical innovations for lower-income patient populations who otherwise lack treatment options.
Find more about BioAccess here: https://www.bioaccessla.com
Follow Julio Martinez-Clark here: https://www.linkedin.com/in/juliomartinezclark/